These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 35656636)

  • 81. Talimogene Laherparepvec (TVEC) for the Treatment of Advanced Melanoma: A Single-Institution Experience.
    Perez MC; Miura JT; Naqvi SMH; Kim Y; Holstein A; Lee D; Sarnaik AA; Zager JS
    Ann Surg Oncol; 2018 Dec; 25(13):3960-3965. PubMed ID: 30298318
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Economic Evaluation of Talimogene Laherparepvec Plus Ipilimumab Combination Therapy vs Ipilimumab Monotherapy in Patients With Advanced Unresectable Melanoma.
    Almutairi AR; Alkhatib NS; Oh M; Curiel-Lewandrowski C; Babiker HM; Cranmer LD; McBride A; Abraham I
    JAMA Dermatol; 2019 Jan; 155(1):22-28. PubMed ID: 30477000
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Observational study of talimogene laherparepvec use for melanoma in clinical practice in the United States (COSMUS-1).
    Perez MC; Zager JS; Amatruda T; Conry R; Ariyan C; Desai A; Kirkwood JM; Treichel S; Cohan D; Raskin L
    Melanoma Manag; 2019 Jul; 6(2):MMT19. PubMed ID: 31406563
    [TBL] [Abstract][Full Text] [Related]  

  • 84. External Validation of a Dutch Predictive Nomogram for Complete Response to T-VEC in an Independent American Patient Cohort.
    Stahlie EHA; Carr MJ; Zager JS; van Akkooi ACJ
    Ann Surg Oncol; 2022 Mar; 29(3):1637-1644. PubMed ID: 34816368
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Intralesional Talimogene Laherparepvec Immunotherapy for Melanoma: A Case Study.
    Ghebrehiwet M; Pavlis J; Gomez-Meade C
    Cureus; 2024 Sep; 16(9):e69605. PubMed ID: 39429342
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Real-World Experience of Talimogene Laherparepvec (T-VEC) in Old and Oldest-Old Patients with Melanoma: A Retrospective Single Center Study.
    Kleemann J; Jäger M; Valesky E; Kippenberger S; Kaufmann R; Meissner M
    Cancer Manag Res; 2021; 13():5699-5709. PubMed ID: 34290528
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Combining talimogene laherparepvec with immunotherapies in melanoma and other solid tumors.
    Dummer R; Hoeller C; Gruter IP; Michielin O
    Cancer Immunol Immunother; 2017 Jun; 66(6):683-695. PubMed ID: 28238174
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Injectables in Head and Neck Cutaneous Melanoma Treatment.
    Rumancik B; Mark L
    Otolaryngol Clin North Am; 2021 Apr; 54(2):425-438. PubMed ID: 33602521
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Talimogene Laherparepvec in Non-Melanoma Cancers.
    Salloum A; Koblinski J; Bazzi N; Zeitouni NC
    J Clin Aesthet Dermatol; 2021 Nov; 14(11):18-25. PubMed ID: 34980955
    [TBL] [Abstract][Full Text] [Related]  

  • 90. The Oncolytic Herpes Simplex Virus Talimogene Laherparepvec Shows Promising Efficacy in Neuroendocrine Cancer Cell Lines.
    Kloker LD; Berchtold S; Smirnow I; Schaller M; Fehrenbacher B; Krieg A; Sipos B; Lauer UM
    Neuroendocrinology; 2019; 109(4):346-361. PubMed ID: 31280274
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Unraveling the Effects of a Talimogene Laherparepvec (T-VEC)-Induced Tumor Oncolysate on Myeloid Dendritic Cells.
    Tijtgat J; De Munck J; Dufait I; Schwarze JK; Van Riet I; Franceschini L; Breckpot K; Aerts JL; Neyns B; Tuyaerts S
    Front Immunol; 2021; 12():733506. PubMed ID: 34777344
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Oncolytic Viruses for the Treatment of Metastatic Melanoma.
    Trager MH; Geskin LJ; Saenger YM
    Curr Treat Options Oncol; 2020 Mar; 21(4):26. PubMed ID: 32266483
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Clinical characteristics and therapy response in unresectable melanoma patients stage IIIB-IIID with in-transit and satellite metastases.
    Zaremba A; Philip M; Hassel JC; Glutsch V; Fiocco Z; Loquai C; Rafei-Shamsabadi D; Gutzmer R; Utikal J; Haferkamp S; Reinhardt L; Kähler KC; Weishaupt C; Moreira A; Thoms KM; Wilhelm T; Pföhler C; Roesch A; Ugurel S; Zimmer L; Stadtler N; Sucker A; Kiecker F; Heinzerling L; Meier F; Meiss F; Schlaak M; Schilling B; Horn S; Schadendorf D; Livingstone E
    Eur J Cancer; 2021 Jul; 152():139-154. PubMed ID: 34102453
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Safe and effective administration of T-VEC in a patient with heart transplantation and recurrent locally advanced melanoma.
    Schvartsman G; Perez K; Flynn JE; Myers JN; Tawbi H
    J Immunother Cancer; 2017; 5():45. PubMed ID: 28642816
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Observational study of talimogene laherparepvec use in the anti-PD-1 era for melanoma in the US (COSMUS-2).
    Sun J; Gastman BR; McCahon L; Buchbinder EI; Puzanov I; Nanni M; Lewis JM; Carvajal RD; Singh-Kandah S; Desai AM; Raskin L; Nielson CM; Ismail R; Zager JS
    Melanoma Manag; 2020 Jun; 7(2):MMT41. PubMed ID: 32821373
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Engineered oncolytic viruses to treat melanoma: where are we now and what comes next?
    Rothermel LD; Zager JS
    Expert Opin Biol Ther; 2018 Dec; 18(12):1199-1207. PubMed ID: 30392405
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Talimogene Laherparepvec: First Global Approval.
    Greig SL
    Drugs; 2016 Jan; 76(1):147-54. PubMed ID: 26620366
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Distinguishing melanophages from tumor in melanoma patients treated with talimogene laherparepvec.
    Audrey-Bayan C; Trager MH; Gartrell-Corrado RD; Rizk EM; Pradhan J; Silverman AM; Lopez A; Marks DK; Niedt G; Geskin LJ; Saenger YM
    Melanoma Res; 2020 Aug; 30(4):410-415. PubMed ID: 32379409
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Talimogene Laherparepvec (T-VEC): An Intralesional Cancer Immunotherapy for Advanced Melanoma.
    Ferrucci PF; Pala L; Conforti F; Cocorocchio E
    Cancers (Basel); 2021 Mar; 13(6):. PubMed ID: 33803762
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Successful treatment with intralesional talimogene laherparepvec in two patients with immune checkpoint inhibitor-refractory, advanced-stage melanoma.
    Seremet T; Planken S; Schwarze JK; Jansen Y; Vandeweerd L; van den Begin R; Tsechelidis I; Lienard D; Del Marmol V; Neyns B
    Melanoma Res; 2019 Feb; 29(1):85-88. PubMed ID: 30211812
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.